ZGNX Brean initiation report (partial) Future Looks Brighter for Zogenix, Initiate with BUY and $2.50 TP Investment Summary We are initiating coverage of Z, Inc. with a BUY rating and a $2.50 TP. Zogenix has commercialized a controversial product, Z ER, and we believe the market under-appreciates the medical value this product brings to patients and pain-treating specialists. Despite the heated debate and intense negative coverage from the media, we are impressed that the product is performing well during early launch days.
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.